Jonathan Wolleben
Stock Analyst at JMP Securities
(4.22)
# 419
Out of 4,884 analysts
202
Total ratings
48.31%
Success rate
15.46%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Reiterates: Market Outperform | $8 | $2.18 | +266.97% | 8 | Jun 27, 2025 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Market Outperform | $84 | $65.77 | +27.72% | 3 | Jun 26, 2025 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $21 | $11.60 | +81.03% | 15 | Jun 26, 2025 | |
| SKYE Skye Bioscience | Reiterates: Market Outperform | $15 | $4.61 | +225.38% | 3 | Jun 24, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Market Outperform | $89 | $20.37 | +337.02% | 9 | Jun 23, 2025 | |
| AURA Aura Biosciences | Reiterates: Market Outperform | $19 | $6.56 | +189.63% | 9 | May 23, 2025 | |
| CLSD Clearside Biomedical | Reiterates: Market Outperform | $5 | $0.81 | +515.54% | 11 | May 16, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $74 → $76 | $50.30 | +51.09% | 10 | May 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Market Outperform | $443 | $298.87 | +48.22% | 12 | Apr 24, 2025 | |
| MBX MBX Biosciences | Initiates: Market Outperform | $38 | $12.47 | +204.73% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $4.76 | +425.21% | 12 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.98 | +58.60% | 3 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $61 | $51.05 | +19.49% | 11 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $19 | $9.62 | +97.51% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $55 | $18.60 | +195.70% | 11 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $8.94 | +101.34% | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $26 | $5.81 | +347.50% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $92 → $91 | $29.80 | +205.37% | 14 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $2.19 | +310.96% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $44.86 | +11.46% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $82.12 | +9.60% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $136.49 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $725.05 | -33.11% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $8.25 | +287.88% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $3.20 | +681.25% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.33 | +2,304.57% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $29.39 | -18.34% | 1 | May 12, 2023 |
ProQR Therapeutics
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.18
Upside: +266.97%
Rhythm Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $84
Current: $65.77
Upside: +27.72%
DBV Technologies
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $11.60
Upside: +81.03%
Skye Bioscience
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $4.61
Upside: +225.38%
Structure Therapeutics
Jun 23, 2025
Reiterates: Market Outperform
Price Target: $89
Current: $20.37
Upside: +337.02%
Aura Biosciences
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.56
Upside: +189.63%
Clearside Biomedical
May 16, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $0.81
Upside: +515.54%
Mirum Pharmaceuticals
May 9, 2025
Maintains: Market Outperform
Price Target: $74 → $76
Current: $50.30
Upside: +51.09%
Madrigal Pharmaceuticals
Apr 24, 2025
Reiterates: Market Outperform
Price Target: $443
Current: $298.87
Upside: +48.22%
MBX Biosciences
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $12.47
Upside: +204.73%
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $25
Current: $4.76
Upside: +425.21%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $11.98
Upside: +58.60%
Mar 10, 2025
Reiterates: Market Outperform
Price Target: $61
Current: $51.05
Upside: +19.49%
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $9.62
Upside: +97.51%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $55
Current: $18.60
Upside: +195.70%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $8.94
Upside: +101.34%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $5.81
Upside: +347.50%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $92 → $91
Current: $29.80
Upside: +205.37%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.19
Upside: +310.96%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $44.86
Upside: +11.46%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $82.12
Upside: +9.60%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $136.49
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $725.05
Upside: -33.11%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $8.25
Upside: +287.88%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $3.20
Upside: +681.25%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.33
Upside: +2,304.57%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $29.39
Upside: -18.34%